Elite in Type 1 Diabetes (T1D)

Bruce A. Perkins

585 University Ave, 8N-845, M5G 2N2, 
Toronto, ON, CA 
Elite in Type 1 Diabetes (T1D)
585 University Ave, 8N-845, M5G 2N2, 
Toronto, ON, CA 
OverviewLocationsClinical Research

Overview

Bruce Perkins practices in Toronto, Canada. Mr. Perkins is rated as an Elite expert by MediFind in the treatment of Type 1 Diabetes (T1D). His top areas of expertise are Type 1 Diabetes (T1D), Diabetic Neuropathy, Sensorimotor Polyneuropathy, and Diabetic Ketoacidosis.

His clinical research consists of co-authoring 232 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 154 articles and participated in 4 clinical trials in the study of Type 1 Diabetes (T1D).

Gender
Male

Locations

585 University Ave, 8N-845, M5G 2N2, Toronto, ON, Canada
Other Locations
Mount Sinai Hospital, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp® (Insulin Aspart Injection)
Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp® (Insulin Aspart Injection)
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Device
Study Phase: Not Applicable
Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)
Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2025
Intervention Type: Drug
Study Drug: Ustekinumab
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 24-Week, Phase 2a Study of Topical Pirenzepine (WST-057) or Placebo in Type 2 Diabetic Patients With Peripheral Neuropathy
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 24-Week, Phase 2a Study of Topical Pirenzepine (WST-057) or Placebo in Type 2 Diabetic Patients With Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: December 16, 2022
Intervention Type: Drug
Study Drug: WST-057 Pirenzepine Free Base Monohydrate
Study Phase: Phase 2
Effect of SGLT2 Inhibition on Improving the Glycemic Performance of the Single Hormone Artificial Pancreas Configuration in Type 1 Diabetes in the Outpatient Setting - A Randomized Placebo Controlled Cross-Over Multicentre Clinical Trial
Effect of SGLT2 Inhibition on Improving the Glycemic Performance of the Single Hormone Artificial Pancreas Configuration in Type 1 Diabetes in the Outpatient Setting - A Randomized Placebo Controlled Cross-Over Multicentre Clinical Trial
Enrollment Status: Completed
Publish Date: June 07, 2022
Intervention Type: Drug, Device
Study Drug: Empagliflozin
Study Phase: Phase 3
PERL (Preventing Early Renal Loss in Diabetes) Continuous Glucose Monitoring (CGM) Study
PERL (Preventing Early Renal Loss in Diabetes) Continuous Glucose Monitoring (CGM) Study
Enrollment Status: Completed
Publish Date: March 29, 2022
Intervention Type: Other, Drug
Alleviating Carbohydrate-Counting Burden in Type 1 Diabetes Using Artificial Pancreas and Sodium Glucose-Linked Transporter 2 Inhibition: A Randomized Open-Label Crossover Trial.
Alleviating Carbohydrate-Counting Burden in Type 1 Diabetes Using Artificial Pancreas and Sodium Glucose-Linked Transporter 2 Inhibition: A Randomized Open-Label Crossover Trial.
Enrollment Status: Completed
Publish Date: June 24, 2021
Intervention Type: Device, Drug, Behavioral
Study Phase: Not Applicable
View 5 Less Clinical Trials

232 Total Publications

Metabolic shifts in plasma amino acids and related metabolites in response to SGLT2 inhibition and hyperglycemia in type 1 diabetes.
Metabolic shifts in plasma amino acids and related metabolites in response to SGLT2 inhibition and hyperglycemia in type 1 diabetes.
Journal: Physiological reports
Published: June 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Perkins's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 23 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile